REFERENCES
2. Petersen KF, Dufour S, Li F, Rothman DL, Shulman GI. Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. JCI Insight 2022;7:e157906.
3. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22 Suppl 2:64-70.
4. Han SK, Baik SK, Kim MY. Correspondence on letter regarding "non-alcoholic fatty liver disease: definition and subtypes". Clin Mol Hepatol 2023;29:817-9.
5. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci 2020;21:5888.
7. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? a cross-sectional comparison with adult treatment panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008;31:562-8.
8. Fu CE, Yong JN, Ng CH, et al. The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Aliment Pharmacol Ther 2023;57:979-87.
9. Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 2023;79:842-52.
10. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
11. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903-13.
12. Lonardo A. Renaming NAFLD to MAFLD: could the lde system assist in this transition? J Clin Med 2021;10:492.
13. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;20:S0168-8278(23)00418.
14. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020;396:565-82.
15. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019;70:1457-69.
16. Regensteiner JG, Reusch JEB. Sex differences in cardiovascular consequences of hypertension, obesity, and diabetes: JACC focus seminar 4/7. J Am Coll Cardiol 2022;79:1492-505.
17. Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia 2023;66:986-1002.
18. Ren R, Zheng Y. Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population. Nutr Metab Cardiovasc Dis 2023;33:1349-57.
19. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19:61-71.e15.
20. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34:1291-326.
21. Goossens GH, Jocken JWE, Blaak EE. Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat Rev Endocrinol 2021;17:47-66.
22. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. focus on clinical aspects and implications for practice and translational research. J Clin Med 2020;9:1278.
23. Allen AM, Therneau TM, Mara KC, et al. Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study. Am J Gastroenterol 2019;114:1764-71.
24. Khalid YS, Dasu NR, Suga H, Dasu KN, Reja D, Shah A, McMahon D, Levine A. Increased cardiovascular events and mortality in females with NAFLD: a meta-analysis. Am J Cardiovasc Dis 2020;10:258-271.
25. Kim Y, Chang Y, Ryu S, et al. Nonalcoholic fatty liver disease and risk of incident young-onset hypertension: effect modification by sex. Nutr Metab Cardiovasc Dis 2023;33:1608-16.
26. Ciardullo S. Commentary on Kim et al. Silent threats: how NAFLD and hypertension team up in young adults, and the role of sex. Nutr Metab Cardiovasc Dis 2023;33:1617-8.
27. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States national health and nutrition examination survey. Aliment Pharmacol Ther 2015;41:65-76.
28. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
29. Lonardo A, Ballestri S, Bedogni G, Bellentani S, Tiribelli C. The fatty liver index (FLI) 15 years later: a reappraisal. Metab Target Organ Damage 2021;1:10.
30. Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37.
31. Ballestri S, Mantovani A, Di Girolamo M, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage 2023;3:1.
